Recent Updates
Recently added Catalysts
DXCM Positive Sentiment

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

Wednesday, October 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dexcom, Inc. has announced the publication of the CONNECT trial results in The New England Journal of Medicine. This landmark study highlights the advantages of continuous glucose monitoring for adults with Type 2 diabetes who are not on insulin. Participants using the Dexcom G7 device showed a notable average reduction in A1C levels.

Market Sentiment Analysis

POSITIVE FACTORS

  • Significant benefits of continuous glucose monitoring demonstrated.
  • Participants experienced an average A1C reduction of 1.6%.
  • Study published in a prestigious journal, enhancing credibility.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,

Frequently Asked Questions

What was the main finding of the CONNECT study?

The CONNECT study found significant benefits of continuous glucose monitoring for Type 2 diabetes patients not on insulin.

Where were the CONNECT study results published?

The results of the CONNECT study were published in The New England Journal of Medicine.

What was the average A1C reduction reported?

Participants using Dexcom G7 experienced an average A1C reduction of 1.6%.

Who conducted the CONNECT trial?

The CONNECT trial was conducted by DexCom, Inc., a leader in glucose biosensing.

ShareAdd on Google
Tags: DXCM Dexcom Type 2 diabetes continuous glucose monitoring A1C reduction CONNECT trial
Last updated: Oct 14, 2026

Biotech snapshot

Cash runway
$1947M liquidity · $0M/mo burn
Low dilution risk
Lead asset
The Seven Continuous Glucose Monitoring SystemPhase 1
Diabetes, Gestational →